The biotechnology company has secured a $175 million private placement financing and an exclusive global license for a late-stage autoimmune asset, positioning it for significant growth.
The healthcare company has announced a change in shareholding by a major investor.
The biotechnology company will present at an upcoming healthcare conference.
The biotechnology company reports positive data from a Phase 2b trial of its investigational therapy for idiopathic pulmonary fibrosis.
The biotherapeutics company publishes new research on the experiences of people living with the rare lung disease IPF, identifying critical gaps in diagnosis, treatment, and quality of life.
The biotechnology company will present data from its Phase 2b trial of deupirfenidone (LYT-100) for the treatment of idiopathic pulmonary fibrosis at an upcoming medical conference.
This biotechnology firm reported mixed annual results, showcasing clinical advancements and improved financials. Despite increased revenue and promising trial outcomes, operational losses and funding challenges persist, reflecting the sector's inherent risks.
The biotechnology company has announced it will publish its annual results and hold a conference call to discuss the findings.
The healthcare company has provided a regulatory update on its holdings.
The biotechnology company has appointed Peel Hunt as a joint UK corporate broker alongside UBS.